Lyfjafyrirtækið Pfizer mun nýta lausnir SidekickHealth í Evrópu til þess að hvetja sjúklinga í að fylgjast nánar með heilsu sinni. Lesa má umfjöllun Northstack um málið hér að neðan.

SidekickHealth and Pfizer just announced a partnership where the pharma giant will deploy SidekickHealth’s digital therapeutics platform across Europe, to empower patients to take control of their health on a number of therapeutic areas. While the exact value of the deal is undisclosed, Northstack has sources describing it as a ‘multi-million dollar deal’.

Pfizer continues to be at the forefront of the transformation of medicine, and we share their vision to empower people to better manage their own health and improve their quality of life,” Sidekick co-founder and chief executive officer Dr. Tryggvi Thorgeirsson said. “Our partnership with Pfizer has the potential to help a vast number of people do just that across multiple geographies, and as such, is precisely what we created Sidekick to do.”

This collaboration follows an earlier partnership between the companies, where SidekickHealth’s platform was used in Austria to help people quit smoking. This time around, they’re expanding the scope. First, for patients in Finland suffering from the two main inflammatory bowel disease (IBD) conditions, ulcerative colitis (UC) and Crohn’s disease (CD), and then for patients with rheumatoid arthritis (RA), atopic dermatitis (AD) and psoriatic arthritis (PsA). During 2020, the platform will also be made available for UC and RA patients in Sweden, Belgium, Netherlands, Ireland, Switzerland and Austria, with plans to expand the reach.

At Pfizer we are committed to enabling health living, and as part of this we are constantly looking for new partners and digital solutions that can significantly improve the lives of patients,” said Rob Day, Western Europe Cluster Lead, Inflammation and Immunology Group at Pfizer.   “Partnering with digital experts such as Sidekick will further support Pfizer’s breakthrough therapies in an area where the burden of disease among patients is significant.”